Roth Capital

In a report published Monday, Roth Capital analyst Joseph Pantginis downgraded the rating on Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Neutral, while reducing the price target from $11 to $6 in view of the strong Auryxia headwinds. Keryx reported its 2Q15 EPS and revenue at ($0.26)...

In a report published Thursday, Roth Capital analyst Anton Brenner maintained a Buy rating and price target of $29 on Sodastream International Ltd (NASDAQ: SODA). The analyst expects gradual recovery to resume for the company in 2H. Following the transition to a health and wellness company...

Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were trading higher by more than 3 percent Tuesday after the company announced a new global collaboration with Sanofi (NYSE: SNY) to "discover, develop and commercialize new antibody cancer treatments in the emerging field of immune-...

In a new report, Roth Capital Partners analyst Philip Shen discusses the solar power industry ahead of its Q2 earnings season. Overall, Shen sees the recent Greece and China-related downward move in solar stocks as a buying opportunity, as the fundamentals of the industry remain solid. Strong...

In a report published Monday, Roth Capital Partners analyst Matt Koranda initiated coverage of Unique Fabricating Inc (NYSE: UFAB) with a Buy rating. Analyst Matt Koranda pointed out that Unique Fabricating was poised for robust growth across multiple end markets in the noise, vibration and...

In a report published Wednesday, Roth Capital analyst Philip Shen initiated coverage of 8Point3 Energy Partners LP (NASDAQ: CAFD) with a Buy rating and $21 price target. The analyst believes that the company is among the "highest quality yieldcos" and that the stock deserves to trade at a premium...

In a report published Thursday, Roth Capital analyst Craig Irwin initiated coverage of Green Plains Partners LP (NASDAQ: GPP) with a Buy rating and a price target of $20. Green Plains Partners is well positioned in the ethanol terminaling and storage space. The company is expected to have a stable...

Roth Capital downgraded China Cord Blood Corp (NYSE: CO) from Buy to Neutral. The price target for China Cord Blood has been raised from $6.50 to $6.75. China Cord Blood shares have gained 15.69 percent over the past 52 weeks, while the S&P 500 index has surged 7.21 percent in the same period....

Roth Capital initiated coverage on Interactive Intelligence Group Inc (NASDAQ: ININ) with a Buy rating. The target price for Interactive Intelligence is set to $58. Interactive Intelligence shares have dropped 15.52 percent over the past 52 weeks, while the S&P 500 index has surged 8.40 percent...

In a report published Thursday, Roth Capital analyst Elemer Piros initiated coverage of Plasmatech Biopharmaceuticals Inc (NASDAQ: PTBI) with a Buy rating and a price target of $16. PlasmaTech develops gene and protein therapies for rare diseases. The company's current developmental portfolio...

Roth Capital initiated coverage on Plasmatech Biopharmaceuticals Inc (NASDAQ: PTBI) with a Buy rating. The target price for Plasmatech is set to $16. Plasmatech shares have dropped 55.81 percent over the past 52 weeks, while the S&P 500 index has surged 9.07 percent in the same period....

In a report published Friday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $4 price target on Palatin Technologies, Inc. (NYSE: PTN). The majority positive vote for flibanserin by the FDA Advisory Committee bodes well for Palatin's bremelanotide. Bremelanotide (BMT) is...

Analysts at Roth Capital initiated coverage on Coeur Mining Inc (NYSE: CDE) with a Buy rating. The target price for Coeur Mining is set to $6.50. Coeur Mining shares have dropped 18.24 percent over the past 52 weeks, while the S&P 500 index has surged 9.66 percent in the same period. Coeur...